PA
RPRX icon

Profund Advisors’s Royalty Pharma RPRX Stock Holding History

Profund Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Sell
4,648
-314
-6% -$16.3K 0.01% 896
2026
Q1 		$238K Sell
4,962
-1,562
-24% -$68.4K 0.01% 918
2025
Q4 		$252K Sell
6,524
-1,621
-20% -$61.8K 0.01% 1004
2025
Q3 		$287K Sell
8,145
-2,477
-23% -$89.7K 0.01% 757
2025
Q2 		$383K Sell
10,622
-992
-9% -$32.9K 0.01% 564
2025
Q1 		$362K Sell
11,614
-4,128
-26% -$131K 0.02% 590
2024
Q4 		$402K Sell
15,742
-663
-4% -$17.6K 0.01% 626
2024
Q3 		$464K Sell
16,405
-404
-2% -$11.2K 0.02% 561
2024
Q2 		$443K Sell
16,809
-3,238
-16% -$89.8K 0.02% 541
2024
Q1 		$609K Buy
20,047
+1,753
+10% +$51.7K 0.02% 512
2023
Q4 		$514K Sell
18,294
-2,123
-10% -$58.3K 0.02% 508
2023
Q3 		$554K Buy
20,417
+2,071
+11% +$61.5K 0.03% 439
2023
Q2 		$564K Buy
18,346
+876
+5% +$29.7K 0.03% 473
2023
Q1 		$629K Sell
17,470
-3,670
-17% -$136K 0.04% 433
2022
Q4 		$835K Buy
21,140
+817
+4% +$34.1K 0.05% 299
2022
Q3 		$817K Sell
20,323
-3,264
-14% -$139K 0.06% 279
2022
Q2 		$992K Sell
23,587
-1,043
-4% -$42.8K 0.06% 262
2022
Q1 		$960K Sell
24,630
-1,869
-7% -$73.4K 0.04% 323
2021
Q4 		$1.06M Buy
26,499
+426
+2% +$16.6K 0.03% 319
2021
Q3 		$942K Buy
26,073
+18,634
+250% +$724K 0.03% 379
2021
Q2 		$305K Buy
7,439
+754
+11% +$32.1K 0.01% 1050
2021
Q1 		$292K Sell
6,685
-384
-5% -$18.2K 0.01% 1001
2020
Q4 		$354K Buy
7,069
+500
+8% +$21.2K 0.02% 727
2020
Q3 		$276K Buy
+6,569
New +$282K 0.01% 712

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's RPRX Position: Q2 2026 in Review

Profund Advisors reduced its Royalty Pharma (RPRX) stake by 6.3% in Q2 2026, selling an estimated $16.3K and leaving 4,648 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #896.

Profund Advisors first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.06M in Q4 2021. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Profund Advisors held 4,648 shares of Royalty Pharma worth $261K as of Q2 2026.
  • Profund Advisors sold 314 Royalty Pharma shares in Q2 2026, an estimated $16.3K.
  • Royalty Pharma made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #896 holding.
  • Profund Advisors first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • Profund Advisors's Royalty Pharma position peaked at $1.06M in Q4 2021.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.